LONDON& HARTFORD, Conn. Aetna today announced that it has completed its acquisition of United Kingdom- based InterGlobal from a group led by its majority shareholder Alchemy Partners. InterGlobal specializes in international private medical insurance for groups and individuals in the Middle East, Asia, Africa and Europe. Aetna Media Contact: Cy
Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King's College London and director, Headache Center, Department of Neurology, University of California, San Francisco, will present results from a randomized, double-blind, placebo-controlled proof-of-conce
eClinicalWorks , a leader in ambulatory healthcare IT solutions, today announced American Health Network is live using eClinicalWorks Care Coordination Medical Record for population health management to manage three Accountable Care Organizations American Health Network of Ohio Care Organization, Franciscan AHN ACO and Indiana Care...
Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib, including obligations relating to...
Baxter International Inc. today announced that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE. ''ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their treatment with fewer steps
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's...
By a News Reporter-Staff News Editor at Biotech Week Calgary Scientific Inc., a company known for creating transformative technology for the medical industry and beyond, announced their latest Class II clearance from the United States Food and Drug Administration. Calgary Scientific worked closely with a number of Radiologists at a world renowned
April 22 HARRISBURG Each day in 2012, an average of 108 men and 109 women in Pennsylvania learned they had cancer. Cancer death rates are down and survival rates are up, but the number of new cancer cases is on the rise in Pennsylvania and throughout the nation. Heine has joined physician advocates with the Pennsylvania Society of Oncology and
We are the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. Our oral, injectable, and respiratory delivery technologies address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products.
Release date- 22042014- PALO ALTO, Calif.- HP Enterprise Services today announced the Colorado Department of Health Care Policy and Financing has signed a $116.9 million contract for HP to implement a new Medicaid management system. HP will serve as the state's Medicaid fiscal agent to strengthen operations and support Colorado's healthcare reform.
LONDON- Sinclair IS Pharma PLC said Wednesday that Non-Executive Director Stuart Swanson has acquired 19,089 shares at a price of 30.5 pence per share on Tuesday. Following this transaction, Swanson holds 4.3 million shares representing 0.99% in the pharmaceutical company. Sinclair shares were trading at 30.86 pence Wednesday midday, down 0.04%.
While such technology has been available for years, Roche now wants the Food and Drug Administration to approve its test as a first-choice option for cervical cancer screening, bypassing the decades-old Pap test. The letter, dated Monday, is signed by 17 patient advocacy groups, including Consumers Union, the Cancer Prevention and Treatment Fund an
April 23 An Indianapolis drug maker will acquire Novartis' animal-health division, which is headquartered in Greensboro, in a $5.4 billion deal announced Tuesday. Novartis AG is a pharmaceutical company based in Basel, Switzerland. Eli Lilly will acquire Novartis' nine manufacturing sites, six research and development facilities, a portfolio of 6
Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Disease or Conditions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability. FDA believes that the Expedited Access PMA program will help patients have more timely access to these...
Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug Application amendment to evaluate PROHEMA in pediatric patients undergoing hematopoietic stem cel
Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug Application amendment to evaluate PROHEMA in pediatric patients undergoing hematopoietic stem c
WASHINGTON, April 23 The U.S. Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. Expedited Access for Premarket Approval Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Disease or Conditions; Draft Guidance for Ind
Siemens Healthcare has announced that the U.S. Food and Drug Administration has cleared the SOMATOM Force computed tomography system the next generation in dual source CT. With two sets of Siemens most innovative X-ray tubes and detectors, the SOMATOM Force extends advanced imaging to all patients, including some of the most challenging: y
Release date- 22042014- Berlin,- Bayer HealthCare today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted an orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation for the treatment of non-cystic fibrosis bronchiectasis. Jorg Moller, Member of the Bayer HealthCa
Release date- 22042014- Today, the U.S. Food and Drug Administration proposed a new program to provide earlier access to high-risk medical devices that are intended to treat or diagnose patients with serious conditions whose medical needs are unmet by current technology. The proposed Expedited Access Premarket Approval Application for Unmet Medical
The proposed Expedited Access Premarket Approval Application for Unmet Medical Needs for Life Threatening or Irreversibly Debilitating Diseases or Conditions program features earlier and more interactive engagement with FDA staff including the involvement of senior management and a collaboratively developed plan for collecting the scientific...
Preparing for the New eCTD Mandates: Mastering the Tools and Strategies** Presented by FDAnews and e-SubmissionsSolutions.com** June 10-11, 2014 Bethesda, MD http://www.fdanews.com/eCTDBethesda. Many drug, biologic and device companies utilizing eCTD can already measure a striking difference through increased first time acceptance rates, shorter
For more information on this research see: Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation, 2014; 85: 381-386. Resuscitation can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Par
By a News Reporter-Staff News Editor at Biotech Week GE Healthcare, a unit of General Electric Company, announced that it received U.S. FDA 510 clearance of its Q.Clear ^ technology- technology that can provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. GE Healthcare's new Q.Clear technology sho
Gentiva Health Services, Inc. announced today that it has scheduled a conference call and webcast on Wednesday, May 7, 2014, at 10:00 a.m. ET to discuss operating results for the first quarter ended March 31, 2014. The May 7, 2014 conference call is open to investment analysts and managers, Company shareholders and others interested in Gentiva Heal